Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MTNR1A | P48039 | 1/20 | 0.51 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.51 |
| ▸ | TSHR | P16473 | 1/20 | 0.51 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.51 |
| ▸ | APP | P05067 | 1/20 | 0.50 |
| ▸ | MEN1 | O00255 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.49 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.49 |
| ▸ | GAA | P10253 | 1/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.48 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6508701 | 0.94 | KDM4E (0.50) | MTNR1AMTNR1BTSHRHSD17B10MEN1 | |
| SCHEMBL6498806 | 0.91 | ACHE (0.50) | MTNR1AMTNR1BAPPMEN1KMT2A | |
| SCHEMBL6505559 | 0.88 | EPHX2 (0.56) | TSHRHSD17B10APPKMT2AGAA | |
| SCHEMBL6500080 | 0.88 | CCR8 (0.50) | APPGAAKDM4E | |
| SCHEMBL6499395 | 0.87 | BCHE (0.56) | TSHRHSD17B10APPGAA | |
| SCHEMBL6496812 | 0.86 | BCHE (0.55) | APPKMT2ASIGMAR1 | |
| SCHEMBL6501980 | 0.86 | GAA (0.69) | TSHRHSD17B10APPGAAKDM4E | |
| SCHEMBL6506029 | 0.86 | LMNA (0.55) | TSHRHSD17B10APPGAA | |
| SCHEMBL6529392 | 0.85 | TSHR (0.48) | MTNR1ATSHRHSD17B10APPGAA | |
| SCHEMBL6498185 | 0.85 | TSHR (0.49) | TSHRHSD17B10APPGAAKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050143372-A1 | Compounds, pharmaceutical compositions and methods of use therefor | MILLENNIUM PHARMACEUTICALS, INC. | 2005-06-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050143372-A1 | Compounds, pharmaceutical compositions and methods of use therefor | CCR8, CCL11, CCR5 | MTNR1A 589/4885MTNR1B 259/4885TSHR 3179/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.